U.S. markets open in 7 hours 11 minutes

DBV Technologies S.A. (DBV.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
10.23-0.09 (-0.87%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.32
Open10.31
BidN/A x N/A
AskN/A x N/A
Day's Range10.13 - 10.42
52 Week Range2.35 - 13.69
Volume197,400
Avg. Volume569,031
Market Cap561.382M
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateMay 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
      GlobeNewswire

      DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

      Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appointment of Mr. Timothy E. Morris, as director, by the DBV Board of Directors, effective March 30, 2021. Mr. Morris will serve as a member of the Audit Committee of the Board. With this addition, the Board comprises nine directors. “We are pleased to welcome Tim Morris as a new director to the DBV Board,” said Michel de Rosen, Chairman of DBV Technologies’ Board of Directors. “Tim brings to DBV more than 20 years of leadership experience in the biopharma sector and he is highly regarded for his finance and commercial capabilities. We believe he will add tremendous value to our Board and DBV as a whole.” Mr. Morris has been the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. Prior to joining Humanigen’s management team, Mr. Morris served as Chair of the Company’s Audit Committee. Mr. Morris has spent more than two decades leading the financial, commercial, and manufacturing functions at several public biopharmaceutical companies, including Iovance, AcelRx, VIVUS, and Questcor (formerly Ribogene). Mr. Morris received his Bachelor of Science in Business with an emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant (Inactive). “The current state of DBV’s European and U.S. regulatory progress and pipeline potential make it an exciting time to join the company,” said Timothy Morris. “I am honored to join DBV and look forward to serving as a member of the Board and Audit Committee and contributing to the success of the Company.” Mr. Morris’ appointment is subject to ratification and will be submitted to a shareholder vote at the Ordinary and Extraordinary General Meeting that DBV Technologies will convene on May 19, 2021. About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). Forward-Looking StatementsThis press release may contain forward-looking statements, including statements regarding Company’s anticipated Ordinary and Extraordinary General Meeting of Shareholders, DBV’s regulatory progress, and the potential of DBV’s pipeline. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual occurrences to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and those associated with scheduling and holding public events, including the impact of the COVID-19 pandemic A further discussion of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV Technologies’ regulatory filings with the French Autorité des Marchés Financiers, DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission, including in DBV Technologies’ Annual Report on Form 10-K for the year ended December 31, 2020, and future filings and reports by DBV Technologies. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com Media ContactAngela MarcucciDBV Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com Attachment PDF Version

    • Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021
      GlobeNewswire

      Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

      Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights03/31/202154,936,687 Total gross of voting rights: 54,936,687 Total net* of voting rights: 54,876,099 * Total net = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

    • DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting
      GlobeNewswire

      DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

      Montrouge, France, March 26, 2021 DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today that Ms. Viviane Monges, director and member of the Audit Committee of the Board of Directors, was appointed as Chairperson of the Board’s Audit Committee in replacement of Ms. Claire Giraut effective March 23, 2021. Ms. Monges has been a member of DBV Technologies’ Board and Audit Committee since May 2019. Ms. Monges currently serves on the Board of Novo Holdings in Denmark, Union Chimique Belge (UCB) in Belgium, Idorsia Pharmaceuticals in Switzerland, and Voluntis SA in France. Earlier in her career, Ms. Monges served in several financial leadership positions at Wyeth Pharmaceuticals, Novartis OTC, Galderma and most recently as CFO of Nestlé’s Business Excellence Division. Ms. Giraut has served as a member of Company’s Board of Directors since June 2016 and as the Chairperson of the Board’s Audit Committee since December 2016. “On behalf of all Board members, the Company’s management team, and shareholders, I thank Claire for her professionalism, expertise, and the commitment with which she has chaired the Audit Committee of DBV Technologies. We appreciate her many contributions and wish her well,” said Michel de Rosen, Chairman of DBV Technologies’ Board of Directors. “We welcome Viviane to this new role as Chair of the Audit Committee and look forward to working with her in this capacity. Viviane’s financial acumen and experience will continue to bring invaluable insight to DBV Technologies.” DBV Technologies and the Board are finalizing the appointment of a new independent director to fill the current vacancy and to join the Audit Committee of the Board. Any such appointment will be provisional and will be submitted to a shareholder vote at the Ordinary and Extraordinary General Meeting that DBV Technologies will convene on May 19, 2021. Details and procedures with respect to DBV Technologies’ Ordinary and Extraordinary General Meeting will be communicated by the Company at a later date. About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). Forward-Looking StatementsThis press release may contain forward-looking statements, including statements regarding Company’s anticipated appointment of a new director and such director’s independence and eligibility to serve on the Audit Committee of Company’s Board of Directors. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual occurrences to differ materially from those described or projected herein include uncertainties related to the availability, qualifications, and independence of candidates to serve as director. A further discussion of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV Technologies’ regulatory filings with the French Autorité des Marchés Financiers, DBV Technologies’ filings and reports with the U.S. Securities and Exchange Commission, including in DBV Technologies’ Annual Report on Form 10-K for the year ended December 31, 2020, and future filings and reports by DBV Technologies. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com Media ContactAngela MarcucciDBV Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com Attachment PDF Version